CliffBio
small molecule

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

NOREPINEPHRINE BITARTRATE

Loss of exclusivity—loss of exclusivity
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameNOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Active ingredientNOREPINEPHRINE BITARTRATE
StrengthEQ 16MG BASE/250ML (EQ 64MCG BASE/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2026
Marketing statusRX

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.